Search Results

SDOH, this study identified data sources, definitions, and measures of SDOH used in observational studies of early-stage cancer. Methods: We conducted a systematic literature review of observational studies focused on the impact of SDOH on early

longitudinal tracking of SMI in patients showed a drop in SMI indicating the probability of cachexia. We further improved the cachexia early detection by employing a multimodal learning approach, where data from clinical notes supplemented the performance of

-refer and more than the NCCN Member Institutions. The NCCN Clinical Practice Guidelines on Oncology (NCCN Guidelines) for Prostate Cancer provides a framework for early detection, evaluation, treatment, and follow-up to help urologists, radiation

in breast, prostate, and lung cancers, and the decline has been steady and continuous since. The reasons for these declines vary by disease, of course. In lung cancer, the declines were primarily driven by tobacco control and early detection. In

Library of NCCN Guidelines. Lung cancer remains the leading cause of cancer-related deaths in the United States and the world; guidance on using effective screening tools for early detection can assist in the effort to decrease mortality rates

Library of NCCN Guidelines App . Early detection and prompt treatment can make a big difference in improving outcomes for ampullary tumors, which occur around a small opening at the junction of the duodenum, bile duct, and pancreatic duct. Ampullary

, and Australia, people have a higher risk of developing skin cancer because they have fair skin, a characteristic that is uncommonly witnessed in other regions. Although guidelines for prevention and early detection of skin cancer are needed in these

this, as it represents the fruits of research labor in prevention (tobacco control), early detection (especially in colorectal cancer), and treatment (especially in breast cancer). Death rates can drop for 2 primary reasons: more true cures and longer

other family members who, if found to be carriers, could tailor their screening to improve the chance for early detection. And of course, testing now has important implications for the patient. We now have new treatment options, such as PARP inhibitors

understood. And until now, the primary importance of knowing who carried pathologic germline mutations was for screening and early detection, not disease management. The success of checkpoint inhibitors (antibodies to CTLA-4, PD-1, or PD-L1) has been